🤫 Unfair Advantage: 10 bargain shares found using this simple toolSee undervalued shares

Trellus Health shares jump 180% on Johnson & Johnson collaboration

Published 14/01/2025, 08:54
© Reuters.  Trellus Health shares jump 180% on Johnson & Johnson collaboration

© Reuters. Trellus Health shares jump 180% on Johnson & Johnson collaboration

ITRM
0.00%

Shares in Trellus Health PLC (AIM:TRLS) soared 180% after the company announced a collaboration with Johnson & Johnson (NYSE:JNJ (NYSE:JNJ)) Health Care Systems Inc.

The partnership will pilot Trellus Health’s digital platform, Trellus Elevate, in the US to support patients with moderate to severe inflammatory bowel disease (IBD).

Under the agreement, Trellus will receive an upfront licensing fee and a fixed monthly management fee during the one-year trial.

The platform integrates data analytics with personalised resilience programs, aiming to help patients manage the emotional and physical challenges of chronic conditions, adhere to treatment plans, and take control of their health.

Eligible patients prescribed Johnson & Johnson therapies will gain access to Trellus Elevate as part of the pharmaceutical company’s patient support programmes.

In the first hour of trading the stock was changing hands for 1.68p, up 1.08p.

Read more on Proactive Investors UK

Disclaimer

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

Should you invest $2,000 in ITRM right now?

With ITRM making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed ITRM alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including ITRM, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is ITRM poised for similar growth? Don't miss the opportunity to find out.

Reveal Undervalued Stocks Now

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.